Appointment

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

By

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

AMA names president-elect

Steven Stack will be the association's youngest president when he takes office in 2015.

Eisai CEO retires

Lonnel Coats is leaving after 18 years with the company.

New president for IOM

Victor Dzau's six-year term starts July 1.

Former FDA communications officer returns to private sector

Former Associate Commissioner for the Office of External Affairs at the U.S. Food and Drug Administration, Virginia Cox has re-joined 3D Communications.

Novartis oncology head goes to Incyte

Herve Hoppenot changed jobs overnight.

Teva names new CEO

Erez Vigodman will be Teva's president and CEO as of February 11.

Teva may have new CEO on deck

The company is rumored to have a name in mind, months after a contentious break with then-CEO Jeremy Levin.

Takeda hire indicates broad change

The company's new president and possible CEO is expected to have significant latitude to change things.

AstraZeneca reveals new CFO and lagging Q3 results

AstraZeneca reveals new CFO and lagging Q3 results

By

The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.

Business briefs: GSK, Roche, Biogen Idec, Forest

FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO

Vivus pins Qsymia hopes on J&J vet after Zook steps down

Vivus pins Qsymia hopes on J&J vet after Zook steps down

By

J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.

Business briefs: GSK, Vivus, Biogen Idec, Astellas, Myriad

GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues

Business briefs: Shire, AthenaHealth, GSK, Novartis

Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK's bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler

Ex-Pfizer chief takes over at troubled Optimer

Ex-Pfizer chief takes over at troubled Optimer

By

Former Pfizer chieftain Hank McKinnell is taking the reins at stock scandal-plagued Optimer—perchance to sell it to Pfizer?

Novartis shakes up C-Suite as sales slide 3%

By

The latest executive change has a touch of deja-vu: Novartis vet Jorg Reinhardt is returning from a stint at Bayer.The company also said it expects 2013 sales to be flat, but sees growth in 2014 and 2015.

AstraZeneca shakeup ousts commercial, R&D chiefs

AstraZeneca shakeup ousts commercial, R&D chiefs

By

AstraZeneca jettisoned its global head of commercial operations and R&D chief, eliminating their roles and curtly suctioning off the company's second-highest layer of management.

FDA regulatory policy chief to take on compounding question

FDA regulatory policy chief to take on compounding question

By

FDA's Jane Axelrad is leaving the Office of Regulatory Policy to head the agency's compounding policy rethink.

Ex-Sepracor chief to lead startup biotech

By

Mark Iwicki, previously president and CEO of Sepracor, has signed on as chief executive officer with oncology-focused pipeline biopharma Blend Therapeutics.

Company news: Endo, Lundbeck, Lilly

Endo is on the hunt for a new President and CEO, Lundbeck lands a $50 million milestone payment and Lilly scales back a Phase III trial.

People news: Teva

Teva names new president/CEO for Americas

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.